• Platform is built on biologically labelled, organ-specific multi-omics data carried by extracellular vesicles isolated from 2ml plasma samples
• Enables differentiated AI-powered biomarker discovery and IVD translation for patient stratification, therapeutic monitoring, surrogate markers and other diagnostic development programs
• Publication of pre-print data, with support from Evotec International GmbH and University College London demonstrates validation of Platform’s capability for liver diseases

Cambridge, UK, and Boston MA, USA, 17 June 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve cancer outcomes for at-risk patients, today announced the commercial launch of its AI Precision Medicine Platform, alongside a pre-print¹ reporting the first validated method for isolating hepatocyte EVs from plasma for organ-specific proteomic and miRNA profiling. Mursla Bio is engaging with potential partners to apply its Platform to additional disease areas, biomarker discovery and IVD translation programs.

The Platform addresses a major gap in liquid biopsy and precision medicine: enabling non-invasive access to organ-specific molecular information from blood with high spatial and biological resolution. Mursla Bio’s Platform is built on its ability to isolate and analyze EVs which are secreted by specific organs into the bloodstream. The Platform reduces non-target background by up to five orders of magnitude compared to standard bulk EV isolation and significantly improves data structure, enhancing prediction model generalization.

The pre-print presents the first multi-layered validation of hepatocyte EV isolation in humans, confirming liver origin through proteomic and nucleic acid markers. Key supporting proteomics data was generated in collaboration with Evotec International GmbH. Patient samples were provided by University College London, with Professor Brian Davidson, a global leader in liver disease surgery and clinical research, contributing as a co-author. The study shows that Mursla Bio’s method yields robust, organ-specific multi-omics data using minimal blood volume, offering a novel scalable approach for biomarker and AI development.

Mursla Bio’s Platform incorporates optimized multi-omics workflows, embedded AI pipelines, and IVD translation processes to convert complex biological signals into practical, regulatory-grade assays. These assays are deployable on standard commercial instruments using patented, PCR and ELISA-like steps designed for clinical adoption. The Platform also underpins the development of EvoLiver™, the Company’s lead clinical program for liver cancer surveillance in cirrhotic patients. Built on multi-omics data from over 300 patients, EvoLiver achieved 86% sensitivity and 88% specificity on a locked, IVD-compatible assay for early-stage hepatocellular carcinoma detection², and has received Breakthrough Device Designation from the FDA³.

Pierre Arsène, Founder and CEO of Mursla Bio, said: "EVs are nature’s native signal enrichment system for long-distance communication between cells and organs. Our platform harnesses this biology to non-invasively access organ-specific, multi-omics data from just a small blood sample. It produces structured, biologically labeled datasets that are optimized for AI and ready to support diagnostic translation. EvoLiver is our first proof point of real-world clinical impact, and we are now expanding access to the platform to advance our pipeline and enable partnerships across other disease areas.”

Mursla Bio is expanding its pipeline and collaborations, with additional organ programs underway in cardiometabolic, lung, and neurological indications. The Platform will support pharma development through dynamic patient stratification, therapeutic response monitoring, surrogate markers and molecular phenotyping across complex disease biology.

For further information on Mursla Bio’s AI Precision Medicine Platform, please visit https://mursla.com/ai-precision-platform/.

1. Pre-print publication: “Organ-specific isolation of hepatocyte extracellular vesicles from human plasma enables tissue-resolved proteomic and miRNA profiling”
2. Press release: Mursla Bio’s EvoLiver surpasses current standards in liver cancer surveillance
3. Press release: Mursla Bio receives FDA Breakthrough Device Designation for EvoLiver™ test

ENDS

About Mursla Bio’s AI Precision Medicine Platform https://mursla.com/ai-precision-platform/

Extracellular vesicles (EVs) are tiny, membrane-wrapped particles released by cells that carry intact and dynamic molecular information reflecting their tissue of origin. By isolating EVs secreted by specific organ(s) into the bloodstream, Mursla Bio generates biologically labelled, multi-omics datasets capturing both proteomic and transcriptomic information from just 2ml of plasma. This allows for robust biomarker discovery and AI model development, especially in complex intended-use populations with limited sample access.

The Platform integrates proprietary organ-specific EV immunocapture, optimized multi-omics workflows, and embedded AI pipelines spanning the full discovery-to-productization continuum. AI supports multiple layers, from surface marker identification and feature selection to assay optimization and model training, enhancing both biological signal quality and statistical power while reducing dependency on very large cohorts. By improving the biological specificity and data structure at the input stage, Mursla Bio’s Platform enables more reproducible and generalizable models for clinical translation, while providing a rich foundation for multi-modal AI models.

About Mursla Bio www.mursla.com

Mursla Bio is a biotech company on a mission to significantly improve cancer outcomes for at-risk patients through the power of Dynamic Biopsy. The Company’s proprietary biopsy platform non-invasively analyzes dynamic biological processes within a specific organ or tissue to assess its health condition. This approach combines the accuracy and disease sub-typing capabilities of tissue biopsies with the ease of liquid biopsy sample collection.

Dynamic Biopsy is made possible by advanced extracellular vesicle (EV) science and an innovative approach called extracellular omics, supported by Mursla Bio’s pioneering technologies. These technologies include organ-specific EV isolation from biofluids for precise targeting, an AI-enabled multi-omics workflow for disease biomarker identification, and a scalable assay platform using optimal biomarkers for clinical use.

The Company’s AI Precision Medicine Platform underpins this technology, offering a full-stack infrastructure for biomarker discovery, assay development, and precision diagnostic productization across disease areas.

Mursla Bio is initially focused on transforming the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths. Mursla Bio is developing its first Dynamic Biopsy-based blood test, EvoLiver™.

Mursla Bio is based in Cambridge, UK and Boston, MA.

For more information please visit: www.mursla.com